BioVex starts phase-I trial of genital herpes vaccine ImmunoVEXHSV2 (PharmaBiz)

In: Biotechnology News

8 Mar 2010

BioVex Inc, a private biotechnology company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced that the first subject had been dosed in the phase-1 study of its live attenuated genital herpes vaccine, ImmunoVEXHSV2.

Excerpt from:
BioVex starts phase-I trial of genital herpes vaccine ImmunoVEXHSV2 (PharmaBiz)

Comment Form

About Biolexis

Biolexis is a premiere online resource for life sciences professionals, investors and entrepreneurs. The site offers personalized information biotechnology news and other biotechnology resources. Information is further organized by industry sector, therapeutic areas, technology focus, service orientation, and location. With Biolexis, you can: access over 5,000 biotechnology news strories and biotechnology articles. Search biotech company information, biotech news, biotech articles and biotech related press releases.

Biotech

    high tech agricultureMicrobiologists icon 3 - Stock illustrationMicrobiologists icon 2 - Stock illustrationMicrobiologists icon 1 - Stock illustrationMicrobiologists icon 4 - Stock illustrationThe Liquid-moving Thingy